Primary and Secondary Angiosarcoma of the Breast

2016 ◽  
Vol 39 (18) ◽  
pp. 1-5
Author(s):  
R. Jared Weinfurtner ◽  
Shannon Falcon
2013 ◽  
Vol 58 (2) ◽  
pp. 208-212 ◽  
Author(s):  
Ailbhe C O'Neill ◽  
Clare D'Arcy ◽  
Enda McDermott ◽  
Ann O'Doherty ◽  
Cecily Quinn ◽  
...  

2010 ◽  
Vol 101 (5) ◽  
pp. 401-407 ◽  
Author(s):  
Jeffrey S. Scow ◽  
Carol A. Reynolds ◽  
Amy C. Degnim ◽  
Ivy A. Petersen ◽  
James W. Jakub ◽  
...  

2008 ◽  
Vol 14 (3) ◽  
pp. 293-298 ◽  
Author(s):  
Angela Moore ◽  
Aaron Hendon ◽  
Molly Hester ◽  
Luis Samayoa

2015 ◽  
Vol 5 ◽  
pp. 45 ◽  
Author(s):  
Christine N Eppelheimer ◽  
Jennifer L Marti ◽  
Amanda Eisenberg ◽  
Qiong Gan ◽  
Rena Shabalova ◽  
...  

Angiosarcoma of the breast is a rare and potentially life-threatening disease. It can present as a palpable mass or subtle erythematous lesion, depending on the predisposing clinical factors. Erythematous skin lesions may be confused for a benign process, which may lead to a delay in diagnosis. We present a case of an 80-year-old woman who developed secondary angiosarcoma after undergoing breast-conserving therapy for Stage IA breast cancer. In this article, we review our experience with a case of secondary angiosarcoma of the breast and discuss the presentation, evaluation, and treatment of this disease. This case demonstrates the importance of vigilance regarding erythematous or papular breast lesions in the setting of prior local radiation.


2021 ◽  
Author(s):  
Michelle Kihara ◽  
Noelle E. Hoven, MD

2016 ◽  
Vol 140 (5) ◽  
pp. 477-481 ◽  
Author(s):  
Saira Shah ◽  
Marilin Rosa

Breast angiosarcoma is an unusual malignancy accounting for approximately 1% of soft tissue sarcomas. It can occur as a primary form without a known precursor or as a secondary form associated with radiotherapy. Adjuvant radiotherapy has a significant role in preventing local recurrence in women treated with conservation therapy for early stage breast carcinoma or multicentric tumors. Postradiation angiosarcoma usually affects the dermis of the breast within the radiation field and may occasionally develop in the breast parenchyma. Compared with the latency of other radiation-associated sarcomas, the latency for breast radiation-associated angiosarcoma is relatively short with a median of 6 years. The risk of developing secondary angiosarcoma does not outweigh the benefit of treatment; therefore, radiation therapy continues to be a mainstay modality in the treatment of breast cancer patients. Early detection is essential because angiosarcomas are associated with a poor prognosis. Wide surgical resection is the standard treatment for these tumors.


2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Yoko Suzuki ◽  
Kohei Taniguchi ◽  
Minami Hatono ◽  
Yukiko Kajiwara ◽  
Yuko Abe ◽  
...  

Cancers ◽  
2021 ◽  
Vol 13 (15) ◽  
pp. 3911
Author(s):  
Markus Notter ◽  
Emanuel Stutz ◽  
Andreas R. Thomsen ◽  
Peter Vaupel

Background: Radiation-associated angiosarcoma of the breast (RAASB) is a rare, challenging disease, with surgery being the accepted basic therapeutic approach. In contrast, the role of adjuvant and systemic therapies is a subject of some controversy. Local recurrence rates reported in the literature are mostly heterogeneous and are highly dependent on the extent of surgery. In cases of locally recurrent or unresectable RAASB, prognosis is very poor. Methods: We retrospectively report on 10 consecutive RAASB patients, most of them presenting with locally recurrent or unresectable RAASB, which were treated with thermography-controlled water-filtered infrared-A (wIRA) superficial hyperthermia (HT) immediately followed by re-irradiation (re-RT). Patients with RAASB were graded based on their tumor extent before onset of radiotherapy (RT). Results: We recorded a local control (LC) rate dependent on tumor extent ranging from a high LC rate of 100% (two of two patients) in the adjuvant setting with an R0 or R2 resection to a limited LC rate of 33% (one of three patients) in patients with inoperable, macroscopic tumor lesions. Conclusion: Combined HT and re-RT should be considered as an option (a) for adjuvant treatment of RAASB, especially in cases with positive resection margins and after surgery of local recurrence (LR), and (b) for definitive treatment of unresectable RAASB.


Sign in / Sign up

Export Citation Format

Share Document